Dark Blue Therapeutics develops precision oncology therapeutics by leveraging novel biological insights to target undrugged cancer dependencies and driver mutations. Their approach aims to provide effective treatments for molecularly defined patient populations with high unmet medical needs.
Funding
$10.6M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Many cancers rely on specific, yet previously untargeted, biological dependencies and driver mutations for survival and growth. Current cancer treatments often fail to address these unique vulnerabilities, leaving significant unmet needs for patients with molecularly defined cancers.
Solution
Dark Blue Therapeutics develops precision oncology therapeutics by identifying and exploiting novel "Achilles heel" dependencies in cancer cells. By partnering with leading academic experts and utilizing cutting-edge discovery science, they create highly targeted medicines designed to disrupt these dependencies. This approach focuses on developing first-in-class drugs with the potential to transform treatment outcomes for patient populations with high unmet medical needs, offering a clear clinical path for single-agent therapies.
Target Audience
The primary target audience includes patients with molecularly defined cancers who have high unmet medical needs, as well as oncologists and researchers seeking more effective and targeted treatment options.
Features
- Focus on undrugged cancer dependencies and driver mutations
- Partnerships with world-leading academic experts for unique target insights
- Development of precision medicines for molecularly defined patient populations
- Pipeline of first-in-class drugs with transformative potential
- Emphasis on adaptive biology and dependency on driver mutations